/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Monopar Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$76.72 0.0164(1.64%) MNPR at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 74.655
Highest Today 79.15
Today’s Open 75.95
Prev. Close 75.94
52 Week High 105.00
52 Week Low 20.16
Day’s Range: Low 74.655 High 79.15
52-Week Range: Low 20.16 High 105.00
1 day return -
1 Week return -8.86
1 month return -5.4
3 month return +106.79
6 month return +126.69
1 year return +218.7
3 year return +2807.43
5 year return +1512.57
10 year return -

Institutional Holdings

HHG PLC 19.00

Adage Capital Partners Gp LLC 9.71

RA Capital Management, LLC 8.29

BlackRock Inc 3.33

Point72 Asset Management, L.P. 1.69

ADAR1 Capital Management LLC 1.64

Geode Capital Management, LLC 1.57

iShares Russell 2000 ETF 1.57

Vanguard Group Inc 1.40

Affinity Asset Advisors, LLC 1.09

Vanguard Institutional Extnd Mkt Idx Tr 0.74

State Street Corp 0.68

Fidelity Small Cap Index 0.66

iShares Russell 2000 Growth ETF 0.61

Ally Bridge Group (NY) LLC 0.56

Northern Trust Corp 0.52

Fidelity Extended Market Index 0.38

UBS Group AG 0.35

Vanguard Russell 2000 ETF 0.31

Millennium Management LLC 0.24

State St Russell Sm Cap® Indx SL Cl I 0.23

Charles Schwab Investment Management Inc 0.21

Schwab Small Cap Index 0.17

NT R2000 Index Fund - NL 0.16

iShares Micro-Cap ETF 0.15

Bank of New York Mellon Corp 0.15

Susquehanna International Group, LLP 0.14

Fidelity Total Market Index 0.13

Morgan Stanley - Brokerage Accounts 0.13

NT R2000 Index Fund - DC - NL - 3 0.13

Barclays PLC 0.12

iShares Russell 2000 Small-Cap Idx Instl 0.11

Extended Equity Market Fund K 0.11

Russell 2500™ Index Fund F 0.10

Citadel Advisors Llc 0.10

Fidelity Series Total Market Index 0.10

Nuveen Small Cap Blend Idx R6 0.09

Spartan Extended Market Index Pool F 0.09

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 507.48 M

PB Ratio 4.0683

PE Ratio 0.0

Enterprise Value 432.30 M

Total Assets 60.29 M

Volume 189268

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:122400 0.1M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:122400 0.1M, FY19:null 0.0M

Annual Net worth FY23:-9484619 -9.5M, FY22:-10494399 -10.5M, FY21:-9079200 -9.1M, FY20:-6222671 -6.2M, FY19:-4125987 -4.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-3437601 -3.4M, Q2/2025:-2453526 -2.5M, Q1/2025:-2624972 -2.6M, Q3/2024:-1304276000 -1304.3M, Q2/2024:-1715309 -1.7M

Fund house & investment objective

Company Information Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow